Cancer Research Annual Meeting 2010  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Published online first on June 2, 2009
[Cancer Research, 10.1158/0008-5472.CAN-09-0354]
This Article
Right arrow Full Text (Online First [PDF])
Right arrow All Versions of this Article:
0008-5472.CAN-09-0354v1
69/12/5007    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ports, M. O.
Right arrow Articles by Cress, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ports, M. O.
Right arrow Articles by Cress, A. E.

Cell, Tumor, and Stem Cell Biology

Extracellular Engagement of {alpha}6 Integrin Inhibited Urokinase-Type Plasminogen Activator–Mediated Cleavage and Delayed Human Prostate Bone Metastasis

Michael O. Ports 1, Ray B. Nagle 1, 2, Gerald D. Pond 3, and Anne E. Cress 1, 4*

1Cancer Biology Interdisciplinary Graduate Program and Departments of 2Pathology, 3Radiology, and 4Cell Biology and Anatomy, University of Arizona, The Arizona Cancer Center, Tucson, Arizona

* To whom correspondence should be addressed. E-mail: acress{at}azcc.arizona.edu.


   Abstract

Expression of {alpha}6 integrin, a laminin receptor, on tumor cell surfaces is associated with reduced patient survival and increased metastasis in a variety of tumors. In prostate cancer, tumor extracapsular escape occurs in part via laminin-coated nerves and vascular dissemination, resulting in clinically significant bone metastases. We previously identified a novel form of {alpha}6 integrin, called {alpha}6p, generated by urokinase-type plasminogen activator-dependent cleavage of the laminin-binding domain from the tumor cell surface. Cleavage increased laminin-dependent migration. Currently, we used the known conformation sensitivity of integrin function to determine if engagement of the extracellular domain inhibited integrin cleavage and the extravasation step of metastasis. We show that {alpha}6 integrin was present on prostate carcinoma escaping the gland via nerves. Both endogenous and inducible levels of {alpha}6p were inhibited by engaging the extracellular domain of {alpha}6 with monoclonal antibody J8H. J8H inhibited tumor cell invasion through Matrigel. A severe combined immunodeficient mouse model of extravasation and bone metastasis produced detectable, progressive osteolytic lesions within 3 weeks of intracardiac injections. Injection of tumor cells, pretreated with J8H, delayed the appearance of metastases. Validation of the {alpha}6 cleavage effect on extravasation was confirmed through a genetic approach using tumor cells transfected with uncleavable {alpha}6 integrin. Uncleavable {alpha}6 integrin significantly delayed the onset and progression of osseous metastases out to six weeks post-injection. The results suggest that {alpha}6 integrin cleavage permits extravasation of human prostate cancer cells from circulation to bone and can be manipulated to prevent metastasis. [Cancer Res 2009;69(12):5007–14]

Key Words: integrin, bone, metastasis, cleavage, uPA







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.